NCT05048875View on ClinicalTrials.gov

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

May 16, 2023

Study Completion Date

September 10, 2024

Conditions
Dengue
Interventions
DRUG

Cohort 1 - Group 1 JNJ High Dose

High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days

DRUG

Cohort 1 - Group 2 JNJ Medium Dose

Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days

DRUG

Cohort 1 - Group 2 JNJ Low Dose

Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days

DRUG

Cohort 1 - Group 1/2 Placebo

Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.

Trial Locations (2)

21202

Johns Hopkins University, Bloomberg School of Public Health, Baltimore

05401

University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH